Flora Raises ¥230M, Total Funding Reaches ¥500M

Key Takeaways

1. Kyoto-based femtech startup Flora has raised ¥230 million (~$1.5 million) in its latest funding round, pushing cumulative capital raised to approximately ¥500 million (~$3.3 million).
2. Investors include Ritsumeikan Social Impact Fund (RSIF), Nagase Future Fund (the CVC arm of Nagase & Co.), PE&HR, and additional financial institution loans.
3. Flora’s consumer app Moonly now serves approximately 200,000 users, while its B2B product Wellflow targets corporate wellness programs for female employees.
4. Fresh capital will fuel expansion of the Flora Expert business-development platform, scale Wellflow enterprise sales, and support the company’s first steps into international markets.

Quick Recap

Flora, a Kyoto-based femtech and AI company dedicated to closing the gender data gap in healthcare, has officially closed a ¥230 million (~$1.5 million) funding round. The announcement was made on April 27, 2026, via a press release and confirmed across multiple outlets including Ritsumeikan Social Impact Fund’s own disclosure. Led by founder and CEO Anna Kreshchenko, a Forbes Asia 30 Under 30 honoree, Flora now carries a cumulative fundraising total of roughly ¥500 million since its founding in December 2020.

Investors, Products, and the Road Ahead

The funding syndicate signals a deliberate strategic intent. Ritsumeikan Social Impact Fund (RSIF) brings university-backed social impact credibility, directly aligned with Flora’s mission of addressing systemic healthcare inequity. Nagase Future Fund, the corporate venture capital arm of Nagase & Co., a major Japanese chemical and life science conglomerate, opens the door to potential enterprise distribution channels, particularly in workplace health and pharmaceutical supply chains.

PE&HR is a returning investor, having backed Flora in earlier bridge rounds, indicating sustained institutional conviction. Flora operates a three-pronged product architecture. Its consumer app Moonly covers menstrual cycle tracking, fertility planning, and menopause symptom management for approximately 200,000 users, building one of the richest proprietary women’s health datasets in Asia.

Its B2B arm, Wellflow, provides corporate clients with a managed platform to support female employee wellbeing, enabling HR departments to monitor and respond to health-related productivity gaps. The third pillar, Flora Expert, turns Flora’s accumulated data and AI models into a rapid hypothesis-testing engine for companies looking to develop women’s health-focused products or services. The new capital will directly scale all three pillars, with an emphasis on expanding Wellflow enterprise sales and advancing international market entry.

Why This Round Matters Right Now?

Japan’s femtech market was valued at approximately USD 5 billion in 2023, representing a 108% year-on-year growth rate. Despite that momentum, the sector remains structurally underserved on the data and technology side. Flora’s CEO Anna Kreshchenko has repeatedly argued that Japan’s femtech ecosystem still lacks sufficiently data-driven, AI-native solutions, with most domestic competitors focused on physical products, e-commerce platforms, or informational newsletters rather than building closed-loop health data systems.

Broader macroeconomic signals reinforce this urgency. Japan’s government has accelerated national-level focus on women’s health, including the launch of dedicated women’s health centers and active grant programs supporting femtech innovation. Flora’s selection among the top 20 startups at HVC KYOTO 2026, one of the largest international healthcare pitch competitions in the Asia-Pacific region, further validates its positioning at the frontier of the sector.

Competitive Landscape: Flora vs. Peers

Flora competes directly with other early-stage femtech platforms in Japan. Two of its closest comparables are Vitalogue Health (Tokyo), which offers at-home hormone testing through its “Canvas” service targeting fertility and menopause, and Fermata (Tokyo/Singapore), a femtech marketplace and B2B ecosystem builder that helps global brands enter the Japanese and Asian markets.

Flora holds a clear structural advantage in data depth and AI integration, making it the only player among these three building a true closed-loop health intelligence platform. Vitalogue Health wins in clinical biomarker precision, while Fermata retains the broadest geographic distribution reach across Asia for consumer femtech brands.

Sci-Tech Today’s Takeaway

I want to be straightforward here: I think this is genuinely one of the more quietly important funding rounds to come out of Japan’s startup ecosystem in early 2026. The number looks modest by global standards. ¥230 million is roughly $1.5 million. But in my experience covering health-tech and emerging market rounds, the most durable companies are not always the ones that raise the largest rounds earliest.

They are the ones that build proprietary data assets while everyone else is distracted by the optics of big checks. Flora has been doing exactly that since 2020. With 200,000 users feeding real health data into its AI systems, Flora now possesses something that no amount of Series A capital can quickly replicate for a late-arriving competitor. I am bullish on Flora’s trajectory, and specifically on its B2B pivot.

Wellflow and Flora Expert transform the user data into an enterprise intelligence product, which is a fundamentally more defensible and scalable business model than a standalone consumer app. The involvement of Nagase Future Fund is a particularly telling signal: an industrial-sector CVC does not typically write checks into femtech startups unless it sees a direct pipeline to its own product development or distribution network.